RecruitingNot ApplicableNCT07360899

Atrial Fibrillation TRIal of Left Atrial Appendage Closure Using Seralene Hemostatic Suture

Left Atrial Appendage Closure During Cardiac Surgery in Atrial Fibrillation Patients With Seralene


Sponsor

Institute of Cardiovascular Diseases, Vojvodina

Enrollment

200 participants

Start Date

Dec 1, 2025

Study Type

INTERVENTIONAL

Conditions

Summary

Atrial fibrillation is a common heart rhythm disorder that increases the risk of stroke. In patients with atrial fibrillation, blood clots most often form in a small structure of the heart called the left atrial appendage. If a blood clot travels from the heart to the brain, it can cause a stroke. Blood-thinning medications are commonly prescribed to reduce the risk of stroke in patients with atrial fibrillation. However, some patients cannot take these medications long-term because of bleeding risk, side effects, or other medical reasons. Closing the left atrial appendage is an alternative approach to reduce the risk of stroke by preventing blood from collecting in this area. When patients undergo cardiac surgery for another indication, closure of the left atrial appendage can be performed during the same operation. This study is designed to evaluate the safety and effectiveness of surgical closure of the left atrial appendage using a device called AtriLASH during cardiac surgery. AtriLASH is a surgical suture-based device intended to close the left atrial appendage. The study will assess whether the left atrial appendage can be safely and effectively closed using this method in patients with atrial fibrillation undergoing cardiac surgery. The information obtained from this study may help determine whether this approach can reduce the risk of stroke and potentially decrease the need for long-term use of blood-thinning medications in selected patients.


Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study tests a new type of surgical suture (stitch) called Seralene for closing off the left atrial appendage (a small pouch in the heart) during heart surgery, to reduce the risk of stroke in people with atrial fibrillation. **You may be eligible if...** - You are 18 or older - You have documented atrial fibrillation (an irregular heart rhythm) - You have a moderate-to-high risk of stroke (CHA₂DS₂-VASc score of 2 or more) - You are already scheduled for heart surgery (such as bypass surgery, valve surgery, or another cardiac procedure) **You may NOT be eligible if...** - There is a blood clot already present in your left atrial appendage, or the anatomy makes closure impossible - Your expected survival is less than 3 months - You are enrolled in another clinical trial that would interfere with this one - You have active or suspected endocarditis (an infection of the heart) Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DEVICELAA closure using the AtriLASH

The intervention consists of surgical closure of the left atrial appendage using the AtriLASH device during cardiac surgery. AtriLASH is a CE-marked, suture-based medical device made of Seralene material and is designed for epicardial closure of the left atrial appendage. The device is applied intraoperatively as part of the planned cardiac surgical procedure in patients with atrial fibrillation. The left atrial appendage is identified and closed using the AtriLASH system according to the manufacturer's instructions for use. No additional incisions or separate procedures are required beyond those necessary for the indicated cardiac surgery. The intervention is performed in all participants allocated to the study arm and is intended to achieve complete exclusion of the left atrial appendage to reduce the potential for blood stasis and thrombus formation.


Locations(1)

Institute of cardiovascular diseases Vojvodina

Kamenitz, Vojvodina, Serbia

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07360899


Related Trials